Is cognitive behavioral therapy more effective than pharmacotherapy for binge spectrum disorders? A systematic review and meta-analysis.

IF 4 2区 医学 Q1 PSYCHIATRY
Myrto T Samara, Niki Michou, Andreas S Lappas, Aikaterini Argyrou, Elissavet Mathioudaki, Dimitra Rafailia Bakaloudi, Eirini Tsekitsidi, Zoi A Polyzopoulou, Nikos Christodoulou, Georgios Papazisis, Michail Chourdakis
{"title":"Is cognitive behavioral therapy more effective than pharmacotherapy for binge spectrum disorders? A systematic review and meta-analysis.","authors":"Myrto T Samara, Niki Michou, Andreas S Lappas, Aikaterini Argyrou, Elissavet Mathioudaki, Dimitra Rafailia Bakaloudi, Eirini Tsekitsidi, Zoi A Polyzopoulou, Nikos Christodoulou, Georgios Papazisis, Michail Chourdakis","doi":"10.1177/00048674231219593","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Binge spectrum disorders are prevalent worldwide. Psychiatric and medical comorbidities are common, and societal costs are significant. Evidence-based treatment remains underutilized. Cognitive behavioral therapy is the recommended first-line treatment, but pharmacotherapy may be easier to access.</p><p><strong>Interventions: </strong>Meta-analytic evidence directly comparing cognitive behavioral therapy with pharmacotherapy is lacking. We aimed to compare the effects of cognitive behavioral therapy interventions with any pharmacological treatment for binge spectrum disorders. We searched PubMed, Embase, CENTRAL, ClinicalTrials.gov and reference lists for randomized controlled trials comparing cognitive behavioral therapy with any pharmacotherapy for bulimia nervosa/binge eating disorder and performed pairwise meta-analytic evaluations.</p><p><strong>Primary outcomes: </strong>Primary outcomes are remission and frequency of binges. Secondary outcomes are frequency of purges, response, eating disorder psychopathology, weight/body mass index, depression, anxiety, quality of life and dropouts.</p><p><strong>Results: </strong>Eleven randomized controlled trials comparing cognitive behavioral therapy with fluoxetine/imipramine/desipramine/methylphenidate/sibutramine were identified (<i>N</i> = 531). Cognitive behavioral therapy was superior to antidepressants in terms of remission, frequency of binges and eating disorder psychopathology. There were no statistically significant differences for any of the individual cognitive behavioral therapy vs drug comparisons in terms of response/depression/anxiety/weight/quality of life/dropouts. Cognitive behavioral therapy was not superior to sibutramine/methylphenidate for the primary outcomes.</p><p><strong>Conclusions: </strong>Data are scarce, comparisons underpowered and, considering the inherent methodological limitations of psychotherapy trials, questions arise regarding the presumed superiority of cognitive behavioral therapy. Further research is needed.</p>","PeriodicalId":8589,"journal":{"name":"Australian and New Zealand Journal of Psychiatry","volume":" ","pages":"308-319"},"PeriodicalIF":4.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian and New Zealand Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00048674231219593","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Binge spectrum disorders are prevalent worldwide. Psychiatric and medical comorbidities are common, and societal costs are significant. Evidence-based treatment remains underutilized. Cognitive behavioral therapy is the recommended first-line treatment, but pharmacotherapy may be easier to access.

Interventions: Meta-analytic evidence directly comparing cognitive behavioral therapy with pharmacotherapy is lacking. We aimed to compare the effects of cognitive behavioral therapy interventions with any pharmacological treatment for binge spectrum disorders. We searched PubMed, Embase, CENTRAL, ClinicalTrials.gov and reference lists for randomized controlled trials comparing cognitive behavioral therapy with any pharmacotherapy for bulimia nervosa/binge eating disorder and performed pairwise meta-analytic evaluations.

Primary outcomes: Primary outcomes are remission and frequency of binges. Secondary outcomes are frequency of purges, response, eating disorder psychopathology, weight/body mass index, depression, anxiety, quality of life and dropouts.

Results: Eleven randomized controlled trials comparing cognitive behavioral therapy with fluoxetine/imipramine/desipramine/methylphenidate/sibutramine were identified (N = 531). Cognitive behavioral therapy was superior to antidepressants in terms of remission, frequency of binges and eating disorder psychopathology. There were no statistically significant differences for any of the individual cognitive behavioral therapy vs drug comparisons in terms of response/depression/anxiety/weight/quality of life/dropouts. Cognitive behavioral therapy was not superior to sibutramine/methylphenidate for the primary outcomes.

Conclusions: Data are scarce, comparisons underpowered and, considering the inherent methodological limitations of psychotherapy trials, questions arise regarding the presumed superiority of cognitive behavioral therapy. Further research is needed.

认知行为疗法比药物疗法对暴饮暴食谱系障碍更有效吗?系统回顾和荟萃分析。
目的:暴饮暴食谱系障碍在全球普遍存在。精神和医疗并发症很常见,社会成本也很高。循证治疗仍未得到充分利用。认知行为疗法是推荐的一线治疗方法,但药物疗法可能更容易获得:缺乏直接比较认知行为疗法和药物疗法的 Meta 分析证据。我们旨在比较认知行为疗法干预与任何药物治疗对暴饮暴食谱系障碍的效果。我们在PubMed、Embase、CENTRAL、ClinicalTrials.gov和参考文献列表中检索了比较认知行为疗法与任何药物疗法治疗暴食症/进食障碍的随机对照试验,并进行了配对荟萃分析评估:主要结果:缓解和暴食频率是主要结果。次要结果包括暴食频率、反应、进食障碍心理病理学、体重/体重指数、抑郁、焦虑、生活质量和辍学:结果:11 项随机对照试验比较了认知行为疗法与氟西汀/丙咪嗪/地西普胺/哌甲酯/西布曲明(N = 531)。在缓解率、暴食频率和饮食失调精神病理学方面,认知行为疗法均优于抗抑郁药物。在反应/抑郁/焦虑/体重/生活质量/辍学方面,认知行为疗法与药物的单项比较差异均无统计学意义。就主要结果而言,认知行为疗法并不优于西布曲明/哌醋甲酯:数据稀缺,对比研究动力不足,考虑到心理疗法试验固有的方法局限性,认知行为疗法的假定优越性会引起质疑。需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.00
自引率
2.20%
发文量
149
审稿时长
6-12 weeks
期刊介绍: Australian & New Zealand Journal of Psychiatry is the official Journal of The Royal Australian and New Zealand College of Psychiatrists (RANZCP). The Australian & New Zealand Journal of Psychiatry is a monthly journal publishing original articles which describe research or report opinions of interest to psychiatrists. These contributions may be presented as original research, reviews, perspectives, commentaries and letters to the editor. The Australian & New Zealand Journal of Psychiatry is the leading psychiatry journal of the Asia-Pacific region.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信